TNXP news

Effective immediately, Tonix announced a second major managed Medicare payer agreement for TONMYA, adding approximately 21 million covered lives and expanding total commercial and government coverage to about 166 million lives.

Tonix Pharmaceuticals has promoted Thomas Englese to Chief Commercial Officer following his instrumental role in the U.S. launch of TONMYA. The management change reflects the company's continued commercial focus on its fibromyalgia and migraine treatments.

Tonix Pharmaceuticals announced that TONMYA net sales increased 197% quarter-over-quarter to approximately $11 million. The company also reported approximately $176.2 million in cash and cash equivalents and provided operational updates on its clinical pipeline.

Tonix Pharmaceuticals announced positive feedback for the design of an adaptive Phase 2 Lyme disease study of TNX-4800, with plans to begin the trial in early 2027. The long-acting monoclonal antibody offers a potential preventative alternative to vaccines that requires fewer doses.

Tonix Pharmaceuticals secured a new managed Medicare agreement covering approximately 9 million lives for TONMYA. This expansion significantly broadens total patient access ahead of the January 2027 effective date, enhancing commercial reach.

Tonix enrolled the first patient in its Phase 2 HORIZON trial testing TNX-102 SL for major depressive disorder. This potential expansion into MDD builds upon the drug's previous success in fibromyalgia and could open a new market if results are positive.

Tonix Pharmaceuticals announced a second commercial payer agreement effective June 1, 2026, adding approximately 17 million U.S. lives in coverage for its fibromyalgia drug TONMYA, bringing total commercial coverage to ~52 million lives (29% of U.S. commercial market). The milestone strengthens mark…

Tonix announced publication of Phase 1 clinical data for TNX-1500 in the Journal of Clinical Immunology, showing the drug was well-tolerated with favorable safety profile. A Phase 2 investigator-initiated kidney transplant study at Massachusetts General Hospital is expected to begin in H2 2026, pote…